OBJECTIVE: To identify patterns of self-reported health problems relating to dose and duration of glucocorticoid intake in unselected patients with rheumatoid arthritis from routine practice. METHODS: Data from 1066 patients were analysed. The clinical status and drug treatment were reported by the physician, health problems during the past 6 months by the patient using a comprehensive list of symptoms. Patients with ongoing glucocorticoid treatment for more than 6 months and current doses of less than 5, 5-7.5 and over 7.5 mg/day prednisone equivalent were compared with a group without any glucocorticoid treatment for at least 12 months. RESULTS: The frequency of self-reported health problems was lowest in the group without glucocorticoid exposition and increased with dosage. Two distinct dose-related patterns of adverse events were observed. A "linear" rising with increasing dose was found for cushingoid phenotype, ecchymosis, leg oedema, mycosis, parchment-like skin, shortness of breath and sleep disturbance. A "threshold pattern" describing an elevated frequency of events beyond a certain threshold value was observed at dosages of over 7.5 mg/day for glaucoma, depression/listlessness and increase in blood pressure. Dosages of 5 mg/day or more were associated with epistaxis and weight gain. A very low threshold was seen for eye cataract (<5 mg/day). CONCLUSION: The associations found are in agreement with biological mechanisms and clinical observations. As there is a paucity of real-life data on adverse effects of glucocorticoids prescribed to unselected groups of patients, these data may help the clinician to adapt therapy with glucocorticoids accordingly and improve the benefit-risk ratio.
OBJECTIVE: To identify patterns of self-reported health problems relating to dose and duration of glucocorticoid intake in unselected patients with rheumatoid arthritis from routine practice. METHODS: Data from 1066 patients were analysed. The clinical status and drug treatment were reported by the physician, health problems during the past 6 months by the patient using a comprehensive list of symptoms. Patients with ongoing glucocorticoid treatment for more than 6 months and current doses of less than 5, 5-7.5 and over 7.5 mg/day prednisone equivalent were compared with a group without any glucocorticoid treatment for at least 12 months. RESULTS: The frequency of self-reported health problems was lowest in the group without glucocorticoid exposition and increased with dosage. Two distinct dose-related patterns of adverse events were observed. A "linear" rising with increasing dose was found for cushingoid phenotype, ecchymosis, leg oedema, mycosis, parchment-like skin, shortness of breath and sleep disturbance. A "threshold pattern" describing an elevated frequency of events beyond a certain threshold value was observed at dosages of over 7.5 mg/day for glaucoma, depression/listlessness and increase in blood pressure. Dosages of 5 mg/day or more were associated with epistaxis and weight gain. A very low threshold was seen for eye cataract (<5 mg/day). CONCLUSION: The associations found are in agreement with biological mechanisms and clinical observations. As there is a paucity of real-life data on adverse effects of glucocorticoids prescribed to unselected groups of patients, these data may help the clinician to adapt therapy with glucocorticoids accordingly and improve the benefit-risk ratio.
Authors: L Heimans; K V C Wevers-de Boer; K Visser; H K Ronday; G M Steup-Beekman; M van Oosterhout; T W J Huizinga; E J Giltay; R C van der Mast; C F Allaart Journal: Clin Rheumatol Date: 2013-07-24 Impact factor: 2.980
Authors: Weston J Smith; Nathan P Oien; Robert M Hughes; Christina M Marvin; Zachary L Rodgers; Junghyun Lee; David S Lawrence Journal: Angew Chem Int Ed Engl Date: 2014-08-22 Impact factor: 15.336
Authors: Manfred Hecking; Johannes Werzowa; Michael Haidinger; Walter H Hörl; Julio Pascual; Klemens Budde; Fu L Luan; Akinlolu Ojo; Aiko P J de Vries; Esteban Porrini; Giovanni Pacini; Friedrich K Port; Adnan Sharif; Marcus D Säemann Journal: Nephrol Dial Transplant Date: 2013-01-17 Impact factor: 5.992
Authors: L Carli; C Tani; F Querci; A Della Rossa; S Vagnani; C Baldini; R Talarico; A d'Ascanio; R Neri; A G Tavoni; S Bombardieri; M Mosca Journal: Clin Rheumatol Date: 2013-03-03 Impact factor: 2.980